{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:21:02Z","timestamp":1794608462979,"version":"4.9.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T00:00:00Z","timestamp":1533168000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201000039I\/Task Order A90"],"award-info":[{"award-number":["HHSN272201000039I\/Task Order A90"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01756","type":"journal-article","created":{"date-parts":[[2018,8,2]],"date-time":"2018-08-02T04:31:38Z","timestamp":1533184298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Immunogenicity and Protection After Vaccination With a Modified Vaccinia Virus Ankara-Vectored Yellow Fever Vaccine in the Hamster Model"],"prefix":"10.3389","volume":"9","author":[{"given":"Justin G.","family":"Julander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Testori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Cheminay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Volkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,8,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J Clin Virol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/10408360490497474","article-title":"Yellow fever: the recurring plague","volume":"41","author":"Tomori","year":"2004","journal-title":"Crit Rev Clin Lab Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1586\/14760584.4.4.553","article-title":"Yellow fever vaccine","volume":"4","author":"Monath","year":"2005","journal-title":"Expert Rev Vaccines"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1016\/j.vaccine.2006.12.015","article-title":"17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005","volume":"25","author":"Barrett","year":"2007","journal-title":"Vaccine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMp1606997","article-title":"Yellow fever in Angola and beyond \u2013 the problem of vaccine supply and demand","volume":"375","author":"Barrett","year":"2016","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMp1702172","article-title":"Yellow fever \u2013 once again on the radar screen in the Americas","volume":"376","author":"Paules","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1038\/s41598-017-05186-3","article-title":"Potential risk of re-emergence of urban transmission of yellow fever virus in Brazil facilitated by competent Aedes populations","volume":"7","author":"Couto-Lima","year":"2017","journal-title":"Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"919","DOI":"10.4269\/ajtmh.2010.10-0001","article-title":"Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States","volume":"82","author":"Monath","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1056\/NEJMp0707161","article-title":"Dengue and yellow fever \u2013 challenges for the development and use of vaccines","volume":"357","author":"Monath","year":"2007","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J Gen Virol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0138348","DOI":"10.1371\/journal.pone.0142802","article-title":"A multicenter, open-label, controlled phase II study to evaluate safety and immunogenicity of MVA smallpox vaccine (IMVAMUNE) in 18\u201340 year old subjects with diagnosed atopic dermatitis","volume":"10","author":"Greenberg","year":"2015","journal-title":"PLoS One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"ofv040","DOI":"10.1093\/ofidofv040","article-title":"Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-Infected individuals: an open-label, Controlled Clinical Phase II Trial","volume":"2","author":"Overton","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-1-4939-6869-5_6","article-title":"Generation and production of modified vaccinia virus Ankara (MVA) as a vaccine vector","volume":"1581","author":"Pavot","year":"2017","journal-title":"Methods Mol Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.antiviral.2006.08.008","article-title":"Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model","volume":"73","author":"Julander","year":"2007","journal-title":"Antiviral Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1086\/320199","article-title":"Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies","volume":"183","author":"Tesh","year":"2001","journal-title":"J Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6607","DOI":"10.1128\/AAC.03368-14","article-title":"BCX4430, a novel nucleoside analog, effectively treats yellow fever in a hamster model","volume":"58","author":"Julander","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1128\/AAC.01635-10","article-title":"Treatment of yellow fever virus with an adenovirus-vectored interferon (DEF201) in a hamster model","volume":"55","author":"Julander","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.antiviral.2013.12.011","article-title":"Humanized monoclonal antibody 2C9-cIgG has enhanced efficacy for yellow fever prophylaxis and therapy in an immunocompetent animal model","volume":"103","author":"Julander","year":"2014","journal-title":"Antiviral Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.4269\/ajtmh.2004.71.306","article-title":"Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease","volume":"71","author":"Sbrana","year":"2004","journal-title":"Am J Trop Med Hyg"},{"key":"B20","doi-asserted-by":"publisher","first-page":"6008","DOI":"10.1016\/j.vaccine.2011.06.034","article-title":"Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model","volume":"29","author":"Julander","year":"2011","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","article-title":"Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity","volume":"28","author":"Monath","year":"2010","journal-title":"Vaccine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1055\/s-0028-1108143","article-title":"[MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author\u2019s transl)]","volume":"99","author":"Stickl","year":"1974","journal-title":"Dtsch Med Wochenschr"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7442","DOI":"10.1016\/j.vaccine.2009.05.095","article-title":"Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain","volume":"27","author":"Suter","year":"2009","journal-title":"Vaccine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1016\/S0264-410X(01)00075-5","article-title":"Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques","volume":"19","author":"Stittelaar","year":"2001","journal-title":"Vaccine"},{"key":"B27","first-page":"1","article-title":"Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"B28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AEM.25.4.539-544.1973","article-title":"Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine","volume":"25","author":"Mason","year":"1973","journal-title":"Appl Microbiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1046\/j.1365-3156.1999.00496.x","article-title":"Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA","volume":"4","author":"Niedrig","year":"1999","journal-title":"Trop Med Int Health"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01756\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T05:22:32Z","timestamp":1604726552000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01756\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,2]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2018.01756"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01756","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,2]]},"article-number":"1756"}}